• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by IRIDEX Corporation

    9/20/22 2:06:59 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $IRIX alert in real time by email
    SC 13D 1 d345929dsc13d.htm SC 13D SC 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No.     )*

     

     

    IRIDEX CORPORATION

    (Name of Issuer)

    Common Stock (par value $0.01/share)

    (Title of Class of Securities)

    462684101

    (CUSIP Number)

    Brent Alexander Roland

    7605 N Shadow Mountain Road, Paradise Valley, AZ, 85253

    480-290-1587

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    September 7, 2022

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box  ☐.

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7(b) for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 462684101   SCHEDULLE 13D  

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Roland Family Support Trust

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☒        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (See Instructions)

     

      PF

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Arizona

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

         8  

      SHARED VOTING POWER

     

      223,688

         9  

      SOLE DISPOSITIVE POWER

     

       10  

      SHARED DISPOSITIVE POWER

     

      223,688

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      881,998

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      5.52%

    14  

      TYPE OF REPORTING PERSON (See Instructions)

     

      OO


    CUSIP No. 462684101    

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Brent Alexander Roland

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☒        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (See Instructions)

     

      PF

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Canada

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

         8  

      SHARED VOTING POWER

     

      461,711

         9  

      SOLE DISPOSITIVE POWER

     

       10  

      SHARED DISPOSITIVE POWER

     

      461,711

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      881,998

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      5.52%

    14  

      TYPE OF REPORTING PERSON (See Instructions)

     

      IN


    CUSIP No. 462684101     Page 2

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Leigh Ann Roland

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☒        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (See Instructions)

     

      PF

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Canada

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

         8  

      SHARED VOTING POWER

     

      15,000

         9  

      SOLE DISPOSITIVE POWER

     

       10  

      SHARED DISPOSITIVE POWER

     

      15,000

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      881,998

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      5.52%

    14  

      TYPE OF REPORTING PERSON (See Instructions)

     

      IN


    CUSIP No. 462684101     Page 3

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Glenn Cuthbert Roland

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☒        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (See Instructions)

     

      PF

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      USA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

         8  

      SHARED VOTING POWER

     

      181,599

         9  

      SOLE DISPOSITIVE POWER

     

       10  

      SHARED DISPOSITIVE POWER

     

      181,599

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      881,998

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      5.52%

    14  

      TYPE OF REPORTING PERSON (See Instructions)

     

      IN


    Item 1.

    Security and Issuer

    This Schedule 13D relates to common stock, par value $0.01 per share (the “Shares), of Iridex Corporation (“IRIX” or the “Company”) with its principal executive offices located at 1212 Terra Bella Avenue, Mountain View, CA, 94043. This statement is filed jointly pursuant to Commission Rule 13d-1(k)(1).

     

    Item 2.

    Identity and Background

    This statement is filed on behalf of the following reporting persons (collectively, the “Reporting Persons”):

     

      (a)

    Brent Alexander Roland, a permanent resident of the United States and citizen of Canada (“B. Roland”).

     

      (b)

    Leigh Ann Roland, a permanent resident of the United States and citizen of Canada (“L. Roland”).

     

      (c)

    Roland Family Support Trust, a trust established under the laws of the State of Arizona (the “Trust”).

     

      (d)

    Glenn Cuthbert Roland, a citizen of the United States (“G. Roland”).

    B. Roland is the contact point for this filing. Set forth on Schedule A to this statement, and incorporated herein by reference, is the (a) name, (b) residence or business address, and (c) present principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is conducted, of each Reporting Person.

    During the last five years, none of the Reporting Persons has been (a) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (b) party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    Item 3.

    Source and Amount of Funds or Other Considerations

    All of the funds used in making the purchase of the Shares described in Item 5 of this Schedule 13D came from the personal funds of the individual Reporting Persons and the funds of the Trust.

     

    Item 4.

    Purpose of Transaction

    The Reporting Persons have purchased the Shares for investment purposes.

    The Reporting Persons leave open the possibility of communicating with management of the Company to discuss future strategy.

     

    Item 5.

    Interest in Securities of the Issuer

    As of the date of this Schedule 13D, each of the Reporting Persons may be deemed to own 881,998 Shares. Such Shares represent 5.52% of Shares outstanding based on 15,985,622 Shares outstanding as of August 11, 2022 as reported in the Company’s 10-Q filed with the Securitas and Exchange Commission for the Company’s Fiscal quarter ended June 30, 2022.


    The Reporting Persons are making this single, joint filing because they may be deemed to constitute a “group” within the meaning of Section 13(d)(3) of the Act. Each Reporting Person expressly disclaims beneficial ownership of any Shares other than those reported herein as being owned by it.

    As of the date of this Schedule 13D, the group has shared voting power with respect to 881,998 Shares. The number of Shares as to which each Reporting Person has sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition is incorporated herein by reference to the cover page.

    The transactions involving the Shares by the Reporting Persons over the past sixty days is provided below. The price reported for the transactions is a weighted average daily price for Shares purchased in multiple transactions. The Reporting Persons undertake to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price.

     

    Date

      

    Reporting Entity

       Number of
    Shares
       Price Per share     

    Where and How
    Transaction
    was Effected

    8/26/22    Brent Roland    10000    $ 2.61      TD Ameritrade
    8/26/22    Brent Roland    7000    $ 2.61      TD Ameritrade
    9/6/22    Brent Roland    5107    $ 2.46      TD Ameritrade
    9/7/22    Brent Roland    1300    $ 2.60      TD Ameritrade
    9/8/22    Brent Roland    10000    $ 2.51      TD Ameritrade
    9/8/22    Brent Roland    451    $ 2.51      TD Ameritrade
    8/23/22    Brent Roland    10000    $ 2.73      Charles Schwab
    8/24/22    Brent Roland    9000    $ 2.72      Charles Schwab
    8/26/22    Brent Roland    10000    $ 2.65      Charles Schwab
    8/26/22    Brent Roland    10000    $ 2.72      Charles Schwab
    8/26/22    Glenn Roland    6758    $ 2.60      TD Ameritrade
    8/30/22    Glenn Roland    18800    $ 2.58      TD Ameritrade
    9/1/2022    Glenn Roland    33241    $ 2.50      Charles Schwab

     

    Page 2


    Date

      

    Reporting Entity

       Number of
    Shares
       Price Per share     

    Where and How
    Transaction
    was Effected

    9/2/2022    Glenn Roland    6759    $ 2.50      Charles Schwab
    8/18/22    Roland Family Support Trust    30000    $ 2.75      Charles Schwab
    8/23/22    Roland Family Support Trust    300    $ 2.68      Charles Schwab
    8/24/22    Roland Family Support Trust    200    $ 2.68      Charles Schwab
    8/24/22    Roland Family Support Trust    20000    $ 2.79      Charles Schwab
    8/26/22    Roland Family Support Trust    7000    $ 2.62      Charles Schwab
    8/28/22    Roland Family Support Trust    20000    $ 2.62      Charles Schwab
    9/13/22    Roland Family Support Trust    22000    $ 2.48      Charles Schwab

     

    Item 6.

    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

    Pursuant to Rule 13d-1(k) promulgated under the Act, the Reporting Persons have entered into an agreement with respect to the joint filing of this statement, and any amendment or amendments hereto, which is attached hereto as Exhibit A.

     

    Item 7.

    Material to Be Filed as Exhibits

    The joint filing agreement entered into among the Reporting Persons is attached hereto as Exhibit A.

     

    Page 3


    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: September 20, 2022

     

    Roland Family Support Trust
    By:  

    /s/ Glenn Cuthbert Roland

    Name:   Glenn Cuthbert Roland
    Title:   Trustee
    Brent Alexander Roland
    By:  

    /s/ Brent Alexander Roland

    Name:   Brent Alexander Roland
    Title:   Individual
    Leigh Ann Roland
    By:  

    /s/ Leigh Ann Roland

    Name:   Leigh Ann Roland
    Title:   Individual
    Glenn Cuthbert Roland
    By:  

    /s/ Glenn Cuthbert Roland

    Name:   Glenn Cuthbert Roland
    Title:   Individual

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

     

    Page 4


    SCHEDULE A

    Additional Information Concerning the Reporting Persons

     

    Name

      

    Residence or Business Address

      

    Present Principal Occupation or
    Employment

      

    Name, Principal Business and
    Address of any Corporation or
    Other Organization in which such
    Employment is Conducted

    Brent Alexander Roland    7605 N Shadow Mountain Rd., Paradise Valley, AZ 85253    Business Owner   

    Tech Round LLC

    8406 E Via De Encanto

    Scottsdale, AZ 85258

    Leigh Ann Roland    7605 N Shadow Mountain Rd., Paradise Valley, AZ 85253    Retired    Not applicable.
    Glenn Cuthbert Roland   

    8533 N. 50th Place;

    Paradise Valley , AZ

    85253

       Business Owner   

    Tech Round LLC

    8406 E Via De Encanto

    Scottsdale, AZ 85258

    Roland Family Support Trust   

    8533 N. 50th Place;

    Paradise Valley , AZ

    85253

       Not applicable.    Not applicable.
    Get the next $IRIX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IRIX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IRIX
    Financials

    Live finance-specific insights

    See more
    • Iridex Reports First Quarter 2025 Financial Results

      MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 29, 2025. First Quarter 2025 Financial Highlights Total revenue was $11.9 million, compared to $11.8 million in the first quarter of 2024Cyclo G6® product family revenue was $3.2 million, an increase of 8% year-over-year, compared to $3.0 million in the prior year quarter Sold 13,900 Cyclo G6 probes compared to 13,300 in the prior year quarterSold 24 Cyclo G

      5/13/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex to Report First Quarter 2025 Financial Results on May 13, 2025

      MOUNTAIN VIEW, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the first quarter 2025 and provide a business update after the close of trading on Tuesday, May 13, 2025. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 and providing conference ID: 698002. A live and re

      4/30/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex to Host Strategic Vision Call on April 16, 2025

      MOUNTAIN VIEW, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will host a special call on April 16, 2025 to introduce Iridex and Novel's strategic vision for the Company following Novel's recent strategic investment in Iridex. The Company's management team will host a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing 888-596-4144 and providing conference ID: 9584140. A live an

      4/9/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Iridex Reports First Quarter 2025 Financial Results

      MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 29, 2025. First Quarter 2025 Financial Highlights Total revenue was $11.9 million, compared to $11.8 million in the first quarter of 2024Cyclo G6® product family revenue was $3.2 million, an increase of 8% year-over-year, compared to $3.0 million in the prior year quarter Sold 13,900 Cyclo G6 probes compared to 13,300 in the prior year quarterSold 24 Cyclo G

      5/13/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex to Report First Quarter 2025 Financial Results on May 13, 2025

      MOUNTAIN VIEW, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the first quarter 2025 and provide a business update after the close of trading on Tuesday, May 13, 2025. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 and providing conference ID: 698002. A live and re

      4/30/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex Announces Preliminary Operational and Financial Results for the First Quarter 2025

      MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the first quarter ended March 29, 2025. First Quarter 2025 Results Total revenue is expected to be between $11.8 million and $12.0 million, compared to $11.8 million in the comparable quarter of 2024Sold approximately 13,900 Cyclo G6 probes, compared to 13,300 in the prior year quarterSold approximately 24 Cyclo G6 Laser Systems, compared to 22 in the

      4/14/25 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    SEC Filings

    See more
    • SEC Form 10-Q filed by IRIDEX Corporation

      10-Q - IRIDEX CORP (0001006045) (Filer)

      5/13/25 4:43:02 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • IRIDEX Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - IRIDEX CORP (0001006045) (Filer)

      5/13/25 4:16:38 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEFA14A filed by IRIDEX Corporation

      DEFA14A - IRIDEX CORP (0001006045) (Filer)

      4/28/25 4:13:02 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Dizon Romeo R bought $1,451 worth of shares (1,305 units at $1.11), increasing direct ownership by 13% to 11,205 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      5/13/25 5:35:24 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Financial Officer Dizon Romeo R bought $116 worth of shares (100 units at $1.16), increasing direct ownership by 1% to 9,900 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      5/12/25 5:53:31 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Financial Officer Dizon Romeo R bought $115 worth of shares (100 units at $1.15), increasing direct ownership by 1% to 9,800 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      5/9/25 4:46:56 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Leadership Updates

    Live Leadership Updates

    See more
    • Iridex Appoints Patrick Mercer as Chief Executive Officer

      MOUNTAIN VIEW, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the appointment of Patrick Mercer as the Company's Chief Executive Officer and President effective October 1, 2024. Previously Mr. Mercer served as the Company's Chief Operating Officer and President. David Bruce, the Company's prior Chief Executive Officer, is transitioning from the Company. Coincident to Mr. Mercer's appointment, Scott Shuda was appointed Executive Chairman of the Company's board of directors. M

      10/3/24 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust

      MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation, headquartered in Mountain View, California, and Imperial College Healthcare NHS Trust in London, today announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse® Transscleral Laser Therapy (TLT) using Iridex' Cyclo G6® Laser and the MicroPulse P3® Delivery Device. This partnership establishes a large-scale enrollment platform to advance clinical research. David I. Bruce, President and CEO of Iridex, shared: "The first patient enrollment in this partnership with Imperial College Healthcare NHS Trust is the first step toward mu

      1/24/24 8:00:00 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Iridex Announces the Appointment of Beverly Huss to its Board of Directors

      MOUNTAIN VIEW, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the appointment of Beverly Huss to its board of directors, effective, March 17, 2022. In connection with Ms. Huss' appointment to the board, the size of the board was increased from five to six members as of the Effective Date. "I am very pleased to welcome Beverly to our board of directors," said Scott Shuda, chairman of the board of Iridex. "Beverly's extensive management and board experience in the medical device industry and proven track record with non-invasive a

      3/21/22 4:05:00 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by IRIDEX Corporation

      SC 13D - IRIDEX CORP (0001006045) (Subject)

      11/23/22 4:57:01 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D filed by IRIDEX Corporation

      SC 13D - IRIDEX CORP (0001006045) (Subject)

      9/20/22 2:06:59 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by IRIDEX Corporation (Amendment)

      SC 13G/A - IRIDEX CORP (0001006045) (Subject)

      2/10/22 8:17:17 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Iridex with a new price target

      Roth Capital reiterated coverage of Iridex with a rating of Buy and set a new price target of $11.00 from $9.00 previously

      5/12/21 11:32:01 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Roth Capital reiterated coverage on IRIDEX with a new price target

      Roth Capital reiterated coverage of IRIDEX with a rating of Buy and set a new price target of $9.00 from $6.00 previously

      3/9/21 8:09:06 AM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Roth Capital reiterated coverage on Iridex with a new price target

      Roth Capital reiterated coverage of Iridex with a rating of Buy and set a new price target of $9.00 from $6.00 previously

      3/3/21 12:29:03 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $IRIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Dizon Romeo R bought $1,451 worth of shares (1,305 units at $1.11), increasing direct ownership by 13% to 11,205 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      5/13/25 5:35:24 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Financial Officer Dizon Romeo R bought $116 worth of shares (100 units at $1.16), increasing direct ownership by 1% to 9,900 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      5/12/25 5:53:31 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Financial Officer Dizon Romeo R bought $115 worth of shares (100 units at $1.15), increasing direct ownership by 1% to 9,800 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      5/9/25 4:46:56 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care